A Relaxin receptor agonist drug (RRA01) for the acute heart failure treatment is developed

by the Sunny Pharmaceutical Company. It is a publicly traded company. The reduction of

cardiovascular death (mortality) was used as the end point (results of the research) for this

investigation. The null hypothesis is "there is no difference in the cardiovascular mortality

reduction between patients who received RRA01 (treatment group) and those who did not

receive RRA01 (control group). Discuss the impact (on the company and/or on the patients)

of the following two possible clinical trial results to the Sunny Pharmaceutical Company,

staff of the company, and the patients. Use a = 0.05 as the significance level for your

discussion.

1. p = 0.002 as the hypothesis test results

2. p = 0.3 as the hypothesis test results.